Table 1 Patient demographics and disease characteristics.
From: Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
Characteristic | Study population ( n =53) |
|---|---|
MM subtype and FLC type, number (%) | |
IgG kappa | 21 (39.6) |
IgG lambda | 6 (11.3) |
IgA kappa | 5 (9.4) |
IgA lambda | 5 (9.4) |
Light chain kappa | 7 (13.2) |
Light chain lambda | 5 (9.4) |
IgD kappa | 1 (1.9) |
Non-secretory myeloma | 1 (1.9) |
Oligosecretory myeloma | 1 (1.9) |
Unknown | 1 (1.9) |
ISS stage at diagnosis, number (%) | |
Stage 1 | 14 (26.4) |
Stage 2 | 8 (15.1) |
Stage 3 | 17 (32.1) |
Unknown | 14 (26.4) |
Number of previous therapies, median (range) | 3 (0–9) |
Types of previous therapies, number (%) | |
PI therapy | 37 (69.8) |
IMiD therapy | 37 (69.8) |
ASCT | 32 (60.4) |
Disease status at blood draw * , number (%) | |
Newly diagnosed | 11 (17.2) |
Early relapsed (1–3 prior lines of therapy) | 28 (43.8) |
Late relapsed (> 3 prior lines of therapy) | 25 (39.1) |
LDH at blood draw†, median (range), U l−1 | 261 (140–1,303) |
M spike at blood draw‡, median (range), g l−1 | 21.5 (0.2–84) |
Light chain ratio, median (range) | |
kappa subtype: kappa/lambda ratio | 376 (2.0–18,723) |
lambda subtype: lambda/kappa ratio | 241 (2.2–23,679) |
Percentage of plasma cells in BM aspirate#, median (range) | 11 (0.2–80) |
